Tag: registration statement

New York, June 03, 2026 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of a registered direct offering (the “Offering”) of approximately $8 million for its client Hitek Global Inc. (NASDAQ: HKIT) (the “Company”), a China-based information technology consulting and solutions service provider.

The short form base shelf prospectus is accessible, and the final prospectus supplement will be accessible within two business days, through SEDAR+.

New York, June 01, 2026 (GLOBE NEWSWIRE) -- Tribeca Strategic Acquisition Corp. (the “Company”), announced today the closing of its initial public offering of 14,000,000 units at a price of $10.00 per unit, which resulted in gross proceeds of $140,000,000. The units are listed on the Nasdaq Global Market (“Nasdaq”) and began trading on May 29, 2026, under the ticker symbol “BIDWU.” Each unit consists of one Class A ordinary share and one right (the “Share Right”) to receive one tenth (1/10) of one Class A ordinary share upon the consummation of an initial business combination.  There are no warrants issued publicly or privately in connection with this offering. Once the securities constituting the units begin separate trading, the Class A ordinary shares and Share Rights are expected to be listed on Nasdaq under the symbols “BID” and “BIDWR,” respectively.

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

SAN DIEGO, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of KinderCare Learning Companies, Inc. (NYSE: KLC) common stock in or traceable to KinderCare’s October 2024 initial public offering (“IPO”), have until October 13, 2025 to seek appointment as lead plaintiff of the KinderCare class action lawsuit. Captioned Gollapalli v. KinderCare Learning Companies, Inc., No. 25-cv-01424 (D. Or.), the KinderCare class action lawsuit charges KinderCare as well as certain of KinderCare’s top executives and directors, KinderCare’s controlling shareholder, and the underwriters of the IPO with violations of the Securities Act of 1933.

NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Lineage, Inc. (NASDAQ: LINE) common stock pursuant and/or traceable to the registration statement issued in connection with Lineage’s July 2024 initial public offering (the “IPO”). If you wish to serve as lead plaintiff, you must move the Court no later than September 30, 2025.